Colony Bankcorp, Inc. and First Reliance Bancshares, Inc. Announce Regulatory Approvals Received for Merger

Colony Bankcorp and First Reliance Bancshares received all required regulatory approvals for their proposed merger, removing a key closing condition. Completion remains subject to other customary conditions, but the approvals increase certainty that First Reliance will be consolidated into Colony. The transaction is chiefly relevant to the two regional-bank equities rather than the broader market.

Analysis

For CBAN, the market will shift from approval risk to execution and accretion credibility. The relevant valuation question is whether projected cost saves can outrun integration expense, deposit repricing, and any credit normalization in the acquired loan book; small-bank combinations frequently require 2-4 quarters before expense synergies are visible in the efficiency ratio. A clean close should modestly improve CBAN's strategic premium by demonstrating that it can use M&A to add scale rather than merely absorb fixed regulatory and technology costs.

The second-order exposure is funding: acquired core deposits are valuable only if their beta remains below CBAN's existing funding costs as rates evolve. If deposit attrition rises following systems conversion, or acquired commercial real-estate credits require higher reserves, the transaction can dilute tangible-book-value growth even when headline EPS accretion is achieved. That makes post-close quarterly deposit balances, noninterest-bearing deposit mix, criticized loans, and the allowance-to-loan ratio more decision-relevant than management's initial synergy target.

There is no clear standalone CBAN directional trade from an approval milestone without the exchange ratio, implied deal spread, pro forma capital ratios, cost-save assumptions, and expected closing date. For merger-arbitrage accounts, FSRL is the cleaner instrument only after confirming the consideration structure and sufficient OTC liquidity; the remaining return should be measured against a limited but nonzero closing-delay, shareholder-vote, and conversion risk. A 1-3 month catalyst path is closing mechanics, while the 6-18 month rerating depends on realized efficiency gains and stable credit costs rather than the transaction announcement itself.

Key Decisions for Investors

• Maintain a neutral CBAN position into closing; do not chase an approval-related move unless pro forma tangible common equity, capital ratios, and transaction consideration indicate accretion materially above current expectations.
• Place a post-close monitoring alert on CBAN: reassess long exposure if quarterly noninterest expense falls versus the pro forma run rate while total deposits remain stable or grow; reduce if deposit attrition or reserve build materially exceeds management's integration assumptions.
• For event-driven capital, evaluate long FSRL / short the appropriate CBAN hedge only after obtaining the exchange ratio, closing date, and average daily OTC liquidity. Require the annualized spread return to compensate for a 60-90 day delay scenario; otherwise pass.
• Use KRE as a sector hedge rather than shorting CBAN outright if taking deal-specific exposure. The key falsifier is a regional-bank risk-off move driven by funding or CRE stress that overwhelms transaction-specific value creation.